Limits...
Complete androgen insensitivity syndrome caused by a deep intronic pseudoexon-activating mutation in the androgen receptor gene

View Article: PubMed Central - PubMed

ABSTRACT

Mutations in the X-linked androgen receptor (AR) gene underlie complete androgen insensitivity syndrome (CAIS), the most common cause of 46,XY sex reversal. Molecular genetic diagnosis of CAIS, however, remains uncertain in patients who show normal coding region of AR. Here, we describe a novel mechanism of AR disruption leading to CAIS in two 46,XY sisters. We analyzed whole-genome sequencing data of the patients for pathogenic variants outside the AR coding region. Patient fibroblasts from the genital area were used for AR cDNA analysis and protein quantification. Analysis of the cDNA revealed aberrant splicing of the mRNA caused by a deep intronic mutation (c.2450-118A>G) in the intron 6 of AR. The mutation creates a de novo 5′ splice site and a putative exonic splicing enhancer motif, which leads to the preferential formation of two aberrantly spliced mRNAs (predicted to include a premature stop codon). Patient fibroblasts contained no detectable AR protein. Our results show that patients with CAIS and normal AR coding region need to be examined for deep intronic mutations that can lead to pseudoexon activation.

No MeSH data available.


Expression of the normally spliced AR mRNA in fibroblasts.The normally spliced AR mRNA was quantified by using primers specific for the normally-spliced variant from RNA extracted from vehicle-treated (0.1% ethanol) patient-derived (T1 and T2) and control (XX31B) fibroblasts. GAPDH was used as the reference gene. The expression in patient samples T1 and T2 was normalized to control sample XX31B vehicle treatment. The bars represent the mean ± SD of 3 independent samples.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5016895&req=5

f3: Expression of the normally spliced AR mRNA in fibroblasts.The normally spliced AR mRNA was quantified by using primers specific for the normally-spliced variant from RNA extracted from vehicle-treated (0.1% ethanol) patient-derived (T1 and T2) and control (XX31B) fibroblasts. GAPDH was used as the reference gene. The expression in patient samples T1 and T2 was normalized to control sample XX31B vehicle treatment. The bars represent the mean ± SD of 3 independent samples.

Mentions: Both aberrant splicing events result in mRNA isoforms which code for 12 additional amino acids (NRIQLSFPLRSP) followed by a premature stop codon (PTC) after amino acid 816. Because of an intron downstream of the PTC, both aberrantly spliced mRNA isoforms are potential targets for the nonsense-mediated decay (NMD) pathway that would lead to the degradation of the AR mRNA7. Compared to LNCaP prostate cancer cells expressing biologically active levels of the AR, both control fibroblasts and patient samples expressed very low amounts of AR mRNA (≤10% of the LNCaP levels, Fig. 2a). This difference was also evident on the AR protein level (Fig. 2c). Additionally, even though the patient fibroblasts expressed overall similar amounts of the AR mRNA as the controls, quantification of the normally-spliced AR mRNA in the patient fibroblasts showed only approximately 10% level of expression as compared to the XX31B control fibroblasts (T1: 9.0–10.9% expression, T2: 11.6–12.9% expression) (Fig. 3). In accordance, immunoprecipitation with a polyclonal anti-AR antibody-coupled to western blotting with a monoclonal anti-AR antibody showed no signs of the AR protein in the patient samples as opposed to two of the control samples. The functionality of androgen signaling in the cells was also tested by examining the ability of the AR agonist R1881 to induce the expression of the AR-target gene FKBP5, but even in the control fibroblasts, the amount of the AR was not sufficient for any induction, whereas the induction was clearly detectable in the LNCaP cells (Fig. 2b).


Complete androgen insensitivity syndrome caused by a deep intronic pseudoexon-activating mutation in the androgen receptor gene
Expression of the normally spliced AR mRNA in fibroblasts.The normally spliced AR mRNA was quantified by using primers specific for the normally-spliced variant from RNA extracted from vehicle-treated (0.1% ethanol) patient-derived (T1 and T2) and control (XX31B) fibroblasts. GAPDH was used as the reference gene. The expression in patient samples T1 and T2 was normalized to control sample XX31B vehicle treatment. The bars represent the mean ± SD of 3 independent samples.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5016895&req=5

f3: Expression of the normally spliced AR mRNA in fibroblasts.The normally spliced AR mRNA was quantified by using primers specific for the normally-spliced variant from RNA extracted from vehicle-treated (0.1% ethanol) patient-derived (T1 and T2) and control (XX31B) fibroblasts. GAPDH was used as the reference gene. The expression in patient samples T1 and T2 was normalized to control sample XX31B vehicle treatment. The bars represent the mean ± SD of 3 independent samples.
Mentions: Both aberrant splicing events result in mRNA isoforms which code for 12 additional amino acids (NRIQLSFPLRSP) followed by a premature stop codon (PTC) after amino acid 816. Because of an intron downstream of the PTC, both aberrantly spliced mRNA isoforms are potential targets for the nonsense-mediated decay (NMD) pathway that would lead to the degradation of the AR mRNA7. Compared to LNCaP prostate cancer cells expressing biologically active levels of the AR, both control fibroblasts and patient samples expressed very low amounts of AR mRNA (≤10% of the LNCaP levels, Fig. 2a). This difference was also evident on the AR protein level (Fig. 2c). Additionally, even though the patient fibroblasts expressed overall similar amounts of the AR mRNA as the controls, quantification of the normally-spliced AR mRNA in the patient fibroblasts showed only approximately 10% level of expression as compared to the XX31B control fibroblasts (T1: 9.0–10.9% expression, T2: 11.6–12.9% expression) (Fig. 3). In accordance, immunoprecipitation with a polyclonal anti-AR antibody-coupled to western blotting with a monoclonal anti-AR antibody showed no signs of the AR protein in the patient samples as opposed to two of the control samples. The functionality of androgen signaling in the cells was also tested by examining the ability of the AR agonist R1881 to induce the expression of the AR-target gene FKBP5, but even in the control fibroblasts, the amount of the AR was not sufficient for any induction, whereas the induction was clearly detectable in the LNCaP cells (Fig. 2b).

View Article: PubMed Central - PubMed

ABSTRACT

Mutations in the X-linked androgen receptor (AR) gene underlie complete androgen insensitivity syndrome (CAIS), the most common cause of 46,XY sex reversal. Molecular genetic diagnosis of CAIS, however, remains uncertain in patients who show normal coding region of AR. Here, we describe a novel mechanism of AR disruption leading to CAIS in two 46,XY sisters. We analyzed whole-genome sequencing data of the patients for pathogenic variants outside the AR coding region. Patient fibroblasts from the genital area were used for AR cDNA analysis and protein quantification. Analysis of the cDNA revealed aberrant splicing of the mRNA caused by a deep intronic mutation (c.2450-118A>G) in the intron 6 of AR. The mutation creates a de novo 5′ splice site and a putative exonic splicing enhancer motif, which leads to the preferential formation of two aberrantly spliced mRNAs (predicted to include a premature stop codon). Patient fibroblasts contained no detectable AR protein. Our results show that patients with CAIS and normal AR coding region need to be examined for deep intronic mutations that can lead to pseudoexon activation.

No MeSH data available.